Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lantheus Medical Imaging
ClinicalTrials.gov Identifier:
NCT01347710
First received: April 11, 2011
Last updated: March 6, 2016
Last verified: August 2014
Results First Received: January 24, 2016  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Condition: Coronary Artery Disease
Interventions: Drug: Flurpiridaz F18
Drug: 99mTechnicium (sestamibi or tetrofosmin)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Flurpiridaz F 18 Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization

Participant Flow:   Overall Study
    Flurpiridaz F 18
STARTED   795 
COMPLETED   764 
NOT COMPLETED   31 
Withdrawal by Subject                2 
Adverse Event                4 
Angio or SPECT not completed                18 
issue with vitals prior to dosing                1 
Lost to Follow-up                1 
Physician Decision                2 
Other                3 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety population, received at least one dose of flurpiridaz F 18

Reporting Groups
  Description
Flurpiridaz F 18 Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization

Baseline Measures
   Flurpiridaz F 18 
Overall Participants Analyzed 
[Units: Participants]
 795 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   458 
>=65 years   337 
Gender 
[Units: Participants]
 
Female   249 
Male   546 
Ethnicity (NIH/OMB) 
[Units: Participants]
 
Hispanic or Latino   43 
Not Hispanic or Latino   708 
Unknown or Not Reported   44 
Race (NIH/OMB) 
[Units: Participants]
 
American Indian or Alaska Native   2 
Asian   8 
Native Hawaiian or Other Pacific Islander   4 
Black or African American   105 
White   652 
More than one race   0 
Unknown or Not Reported   24 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity   [ Time Frame: 60 days ]

2.  Primary:   Diagnostic Efficacy of Flurpiridaz PET MPI Specificity Versus SPECT MPI Specificity   [ Time Frame: 60 days ]

3.  Secondary:   Diagnostic Efficacy of Flurpiridaz F18 PET MPI Sensitivity Versus SPECT MPI Sensitivity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.   [ Time Frame: 60 days ]

4.  Secondary:   Diagnostic Efficacy of Flurpiridaz F18 PET MPI Specificity Versus SPECT Specificity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.   [ Time Frame: 60 days ]

5.  Secondary:   Diagnostic Performance Evaluation of Localization of CAD for Sensitivity (PETVsSPECT).   [ Time Frame: 60 days ]

6.  Secondary:   Diagnostic Performance Evaluation of Localization of CAD for Specificity (PETVsSPECT).   [ Time Frame: 60 days ]

7.  Secondary:   Diagnositic Performance Evaluation of Multivessel Disease (PETvsSPECT).   [ Time Frame: 60 days ]

8.  Secondary:   Diagnositic Performance Evaluation of Multivessel Disease (PETvsSPECT).   [ Time Frame: 60 days ]

9.  Secondary:   Overall Summary of Sensitivity of PET MPI vs SPECT MPI; Image Quality Excellent or Good   [ Time Frame: 60 days ]

10.  Secondary:   Overall Summary of Specificity of PET MPI vs SPECT MPI; Image Quality of Excellent or Good   [ Time Frame: 60 days ]

11.  Secondary:   Image Quality of Rest and Stress (PET vs SPECT).   [ Time Frame: 60 days ]

12.  Secondary:   Diagnostic Certainty in PET MPI and SPECT MPI   [ Time Frame: 60 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: CMO
Organization: Lantheus Medical Imaging
phone: 978-671-8544
e-mail: c.orlandi@lantheus.com



Responsible Party: Lantheus Medical Imaging
ClinicalTrials.gov Identifier: NCT01347710     History of Changes
Other Study ID Numbers: BMS747158-301
Study First Received: April 11, 2011
Results First Received: January 24, 2016
Last Updated: March 6, 2016
Health Authority: United States: Food and Drug Administration